Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still AheadThe Motley Fool • 08/20/26
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNXBusiness Wire • 08/17/26
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even MoreThe Motley Fool • 08/14/26
Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)Seeking Alpha • 08/14/26
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This YearZacks Investment Research • 08/11/26
Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?The Motley Fool • 08/07/26
VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View RaisedZacks Investment Research • 08/04/26
VRTX Q2 Earnings Call Highlights Launch Momentum & Higher OutlookZacks Investment Research • 08/04/26
Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth StorySeeking Alpha • 08/04/26
Vertex (VRTX) Q2 Earnings Preview: What You Should Know Beyond the Headline EstimatesZacks Investment Research • 07/29/26
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to ConsiderZacks Investment Research • 07/28/26